NPS Pharmaceuticals NPSP

By Jason Boyce : NPS Pharmaceuticals ( NPSP ) is an FDA run-up candidate and possibly one to tuck away for a long-term hold. Quick facts Two products gearing up for approval …

NPS Pharmaceuticals ( NPSP ): Q4 EPS of -$0.10 beats by $0.01 . Revenue of $26.3M (+9.6% Y/Y) in-line. ( PR ) Post your comment!

By Kapitall : Quarterly earnings reports can have big effects on a biotech stock price, especially if a company has just launched a newly approved drug. For ideas on how to find which stocks to follow, we ran a screen on next week's reporting companies from the biotech industry. We screened these

Wedbush initiates coverage on NPS Pharmaceuticals ( NPSP ) at Outperform with a lofty $14 price target. Analysts with the firm expect that not only will Gattex win FDA approval, but that the cancer drug will also deliver $252M in global revenue in 2015. Post your comment!

NPS Pharmaceuticals ( NPSP +1.8% ) trades higher after the FDA accepts its Gattex drug application for review. Slicing through the firm's statement a bit - it appears that it didn't land a coveted "priority" review from the FDA. Post your comment!

… pipelines. Here are two high risk/high reward stocks agressive investors should consider within the sector. NPS Pharmaceuticals ( NPSP ) , a clinical-stage biopharmaceutical company, engages in the development specialty therapeutics for gastrointestinal …

By Kapitall : A company's owners (or, shareholders) have very different goals than company management. Specifically, a company's owners seek to maximize the value of the company, while company management often wishes to maximize personal wealth. Corporate governance policies mitigate these ...